1
|
Di Marco T, Bianchi F, Sfondrini L, Todoerti K, Bongarzone I, Maffioli EM, Tedeschi G, Mazzoni M, Pagliardini S, Pellegrini S, Neri A, Anania MC, Greco A. COPZ1 depletion in thyroid tumor cells triggers type I IFN response and immunogenic cell death. Cancer Lett 2020; 476:106-119. [PMID: 32061953 DOI: 10.1016/j.canlet.2020.02.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2019] [Revised: 02/07/2020] [Accepted: 02/10/2020] [Indexed: 12/23/2022]
Abstract
The coatomer protein complex zeta 1 (COPZ1) represents a non-oncogene addiction for thyroid cancer (TC); its depletion impairs the viability of thyroid tumor cells, leads to abortive autophagy, ER stress, UPR and apoptosis, and reduces tumor growth of TC xenograft models. In this study we investigated the molecular pathways activated by COPZ1 depletion and the paracrine effects on cellular microenvironment and immune response. By comprehensive and target approaches we demonstrated that COPZ1 depletion in TPC-1 and 8505C thyroid tumor cell lines activates type I IFN pathway and viral mimicry responses. The secretome from COPZ1-depleted cells was enriched for several inflammatory molecules and damage-associated molecular patterns (DAMPs). Moreover, we found that dendritic cells, exposed to these secretomes, expressed high levels of differentiation and maturation markers, and stimulated the proliferation of naïve T cells. Interestingly, T cells stimulated with COPZ1-depleted cells showed increased cytotoxic activity against parental tumor cells. Collectively, our findings support the notion that targeting COPZ1 may represent a promising therapeutic approach for TC, considering its specificity for cancer cells, the lack of effect on normal cells, and the capacity to prompt an anti-tumor immune response.
Collapse
Affiliation(s)
- Tiziana Di Marco
- Molecular Mechanisms Unit, Department of Research, Fondazione IRCCS Istituto Nazionale Dei Tumori, Via G.A. Amadeo, 42, 20133, Milan, Italy.
| | - Francesca Bianchi
- Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale Dei Tumori, Via G.A. Amadeo, 42, 20133, Milan, Italy.
| | - Lucia Sfondrini
- Dipartimento di Scienze Biomediche per La Salute, University of Milan, Via Mangiagalli, 31, 20133, Milan, Italy.
| | - Katia Todoerti
- Hematology Unit, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Via Francesco Sforza, 35, 20122, Milan, Italy.
| | - Italia Bongarzone
- Molecular Mechanisms Unit, Department of Research, Fondazione IRCCS Istituto Nazionale Dei Tumori, Via G.A. Amadeo, 42, 20133, Milan, Italy.
| | | | - Gabriella Tedeschi
- Department of Veterinary Medicine, University of Milan, Via Celoria, 10, 20133, Milan, Italy; Fondazione Filarete, Via Celoria, 10, 20133, Milan, Italy.
| | - Mara Mazzoni
- Molecular Mechanisms Unit, Department of Research, Fondazione IRCCS Istituto Nazionale Dei Tumori, Via G.A. Amadeo, 42, 20133, Milan, Italy.
| | - Sonia Pagliardini
- Molecular Mechanisms Unit, Department of Research, Fondazione IRCCS Istituto Nazionale Dei Tumori, Via G.A. Amadeo, 42, 20133, Milan, Italy.
| | - Sandra Pellegrini
- Institut Pasteur, Unit of Cytokine Signaling, Inserm U1221, 75724, Paris, France.
| | - Antonino Neri
- Hematology Unit, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Via Francesco Sforza, 35, 20122, Milan, Italy; Department of Oncology and Hemato-oncology, University of Milan, Italy Via Francesco Sforza, 35, 20122, Milan, Italy.
| | - Maria Chiara Anania
- Molecular Mechanisms Unit, Department of Research, Fondazione IRCCS Istituto Nazionale Dei Tumori, Via G.A. Amadeo, 42, 20133, Milan, Italy.
| | - Angela Greco
- Molecular Mechanisms Unit, Department of Research, Fondazione IRCCS Istituto Nazionale Dei Tumori, Via G.A. Amadeo, 42, 20133, Milan, Italy.
| |
Collapse
|